📰 Michael Olymbios News
Michael Olymbios News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Michael Olymbios. Real-time updates on events, politics, business and more.
July 13, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA). Such investors are...
July 13, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA). Such investors are...
July 6, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA). Such investors are...
June 29, 2022
SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your...
June 28, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA). Such investors are...
June 23, 2022
SAN FRANCISCO, June 23, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your...
June 22, 2022
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of CareDx,...
June 20, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA). Such investors are...
June 9, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA). Such investors are...
June 6, 2022
In a recent study, Michael Olymbios, MD, the medical director of heart transplantation for Natera Inc., and colleagues found that a noninvasive blood test may help predict rejection after a heart transplant.